Scarica l'app Stockscreener
387.77
3.55%
13.31
Dopo l'orario di chiusura:
387.50
-0.27
-0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$374.46
Aprire:
$377.605
Volume 24 ore:
2.03M
Relative Volume:
1.22
Capitalizzazione di mercato:
$99.42B
Reddito:
$11.42B
Utile/perdita netta:
$3.64B
Rapporto P/E:
27.72
EPS:
13.99
Flusso di cassa netto:
$3.50B
1 W Prestazione:
+3.41%
1M Prestazione:
-17.29%
6M Prestazione:
-14.44%
1 anno Prestazione:
-16.52%
Intervallo 1D:
$375.00
$388.25
Intervallo di 1 settimana:
$362.50
$390.56
Portata 52W:
$362.50
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
387.77 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.55 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.93 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
637.56 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.10 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals: The Stock Hasn't Dropped Enough Yet (NASDAQ:VRTX) - Seeking Alpha
Vertex HQ refinanced for $1 billion - The Business Journals
Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings May Just Be The Starting Point - Yahoo Finance
Vertex Pharmaceuticals: A Biotech Powerhouse Poised for Rebound After Oversold Correction - AInvest
Vertex Pharmaceuticals Is A Strong Buy After The Recent Pullback (Upgrade) (NASDAQ:VRTX) - Seeking Alpha
Goldman Sachs reiterates Buy rating on Vertex stock, citing diversification By Investing.com - Investing.com South Africa
The week in pharma: action, reaction and insight – week to August 8 - The Pharma Letter
Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial - MSN
Vertex unveils positive study data for CF triple-combination regimens; shares jump - FirstWord Pharma
KOL Views: Vertex's triplet data exceed expectations – implications for CF landscape - FirstWord Pharma
Vertex Analyst Rating Lowered by B of A Securities; VERX Stock Price Target Cut to $34.00 - AInvest
Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat - MSN
South African Patient Groups Urge Antitrust Probe into Vertex Pharmaceuticals Over Cystic Fibrosis Drug Pricing - geneonline.com
Hedge Fund and Insider Trading News: Ken Griffin, DE Shaw, Bobby Jain, Jim Cramer, Rokos Capital Management, Point72 Asset Management, Vertex Pharmaceuticals Inc (VRTX), Galaxy Digital Inc (GLXY), and More - Insider Monkey
Vertex Pharmaceuticals Plunges 2.69%—Is This the Bottom for Vertex Pharmaceuticals? - AInvest
Advocates urge South Africa to reopen antitrust probe into Vertex Pharmaceuticals - statnews.com
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals' Headquarters in Boston Seaport District - MarketScreener
Stock Analysis | Vertex Pharmaceuticals OutlookNavigating Mixed Signals and Market Uncertainty - AInvest
Vertex Pharma CEO Kewalramani buys shares worth $3.89 million - Investing.com
RMR Group secures $1 billion mortgage for Vertex Pharmaceuticals HQ By Investing.com - Investing.com Australia
The RMR Group Announces $1.0 Billion Refinancing of Vertex Pharmaceuticals’ Headquarters in Boston Seaport District - MarketScreener
Vertex Pharmaceuticals Executives Make Significant Stock Purchases - TradingView
Vertex Pharmaceuticals Reports Q2 2025 Revenue Growth, Net Income Turns Positive Amidst Challenges - AInvest
Vertex Pharmaceuticals (VRTX) Reports Strong Q2 2025 Revenue Growth with US$2,965 Million - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Vertex Pharmaceuticals: Guggenheim maintains a 'Buy' Rating, The Target Price is $546 - AInvest
The Escalator: Geron, Vertex Pharmaceuticals, Butler/Till and more - Medical Marketing and Media
Vertex Pharmaceuticals Shares Rise After Upgrade From Wells Fargo - MarketScreener
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript - Insider Monkey
Vertex stock price target lowered to $411 by Canaccord on mixed pipeline updates - Investing.com
Vertex Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Vertex tops estimates on cystic fibrosis treatment strength, new products - MSN
Vertex’s Journavx successor culled after falling short in Phase II trial - Yahoo Finance
7 Reasons Why Vertex Pharmaceuticals Is a No-Brainer Stock to Buy on the Dip - MSN
Vertex Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
Vertex Pharmaceuticals: Strong Growth and Strategic Advances - TipRanks
Vertex falls after FDA doubts broad use of chronic pain drug - The Boston Globe
Vertex Pharmaceuticals Reports 12% Revenue Increase in Q2 2025 - The Globe and Mail
Growing, pain: Journavx on the move as Vertex reports 2Q hitches - BioWorld MedTech
Vertex Pharmaceuticals Halts Development of VX-993 After Phase II Trial Fails to Show Pain Relief Benefit - geneonline.com
Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today - Yahoo Finance
Vertex Pharmaceuticals stock hits 52-week low at $377.78 - Investing.com
Weakness In Vertex Stock Seen As Buying Opportunity - Benzinga
These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results - Benzinga
Cantor Equity Partners, Inc. shares fall 2.41% intraday as Vertex Pharmaceuticals' price targets are adjusted by multiple analysts. - AInvest
Vertex stock price target lowered to $478 at H.C. Wainwright on pain program setbacks - Investing.com Australia
Vertex Pharmaceuticals: A Long-Term Growth Story Fueled by Financial Discipline and Pipeline Breakthroughs - AInvest
Vertex’s strong quarter unable to undo pain from VX-993 woes - The Pharma Letter
VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial - TradingView
Vertex VX-993 Misses Primary Endpoint in Mid-Stage Trial, Ending Investigation for Acute Pain - Patient Care Online
Relative Strength Alert For Vertex Pharmaceuticals - Nasdaq
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.94%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):